Amyris, IDRI post positive preclinical results for COVID-19 vaccine

By The Science Advisory Board staff writers

February 22, 2021 -- Amyris, in partnership with the Infectious Disease Research Institute (IDRI), has released preliminary data from a preclinical study of its RNA COVID-19 vaccine platform.

Amyris announced that it entered into a collaboration agreement and exclusive license with the IDRI in October 2020 to advance a novel RNA vaccine platform, including the development of a COVID-19 vaccine.

Preliminary data from the study of a self-adjuvanting RNA COVID-19 vaccine candidate developed using IDRI's nanostructured lipid carrier (NLC) vaccine platform demonstrated a significant level of antibody production against the SARS-CoV-2 spike protein.

Manufacturing of the vaccine is possible with easily sourced components, including Amyris' sustainable sugarcane squalene, which would replace the use of traditional shark-derived squalene in vaccines. The Amyris-IDRI platform's manufacturing process is also designed with a well-established oil-in-water emulsion technology.

The Amyris-IDRI COVID-19 vaccine candidate can be stored at refrigerator temperatures for prolonged periods and for several months at room temperature, potentially improving vaccine distribution.

The Amyris-IDRI vaccine platform will be advancing to phase I clinical trials with the support of the Portuguese government and other partners.

Amyris, IDRI to partner on RNA vaccines
Amyris and the Infectious Disease Research Institute (IDRI) have announced that they will collaborate on the development of a new RNA vaccine platform,...
Amyris partners with IDRI on scalable vaccine platform
Amyris and the Infectious Disease Research Institute (IDRI) have inked a binding term sheet for the development of a planned COVID-19 RNA vaccine technology...

Copyright © 2021

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter